natgillin/translations-raw huggingface dataset:
In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil as part of a regimen containing a boosted protease inhibitor. 
V drugih študijah (prospektivne in presečne) so najbolj izrazito zmanjšanje MGK opazili pri bolnikih, zdravljenih z dizoproksiltenofoviratom kot del režima, ki je vseboval okrepljenega zaviralca proteaze.
Following intravenous administration the volume of distribution of emtricitabine was approximately 1.4 l/kg. 
Po intravenskem odmerku je volumen porazdelitve emtricitabina znašal približno 1,4 l/kg.
The clinical implications of such an association are unknown; however, the potential for an increased frequency and severity of efavirenz-associated adverse events cannot be excluded. 
Klinični pomen te povezave ni znan, vendar pa možnost za povečanje pogostnosti in resnosti z efavirenzom povezanih neželenih učinkov ne more biti izključena.
Pharmacotherapeutic group: Antiviral for systemic use, antivirals for treatment of HIV infections, combinations, ATC code: J05AR06 
Farmakoterapevtska skupina: zdravila za sistemsko zdravljenje virusnih infekcij, antivirusna zdravila za zdravljenje infekcij s HIV-om, kombinacije, oznaka ATC: J05AR06.
Some patients have had blood tests or symptoms indicating that their hepatitis has got worse after stopping emtricitabine or tenofovir disoproxil (two of the three components of Atripla). 
Pri nekaterih bolnikih so krvne preiskave ali simptomi pokazali, da se je hepatitis poslabšal po prenehanju jemanja emtricitabina ali dizoproksiltenofovirata (dve od treh učinkovin zdravila Atripla).
Efavirenz, one of the active components of Atripla, may remain in your blood for a time after therapy is stopped. 
Efavirenz, ena izmed učinkovin zdravila Atripla, lahko ostane v krvi še nekaj časa po prenehanju zdravljenja.
Data on the clinical translation of the decrease in pharmacokinetic exposure are not available. 
Podatki o kliničnem pomenu zmanjšanja farmakokinetične izpostavljenosti niso na voljo.
Experience with efavirenz in patients who discontinued other antiretroviral agents of the NNRTI class is limited. 
Izkušnje z efavirenzom pri bolnikih, ki so prenehali jemati druga protiretrovirusna zdravila razreda NNRTI, so omejene.
Biliary fibrosis has been observed in rats. 
Pri podganah so opazili biliarno fibrozo.
The silica gel desiccant is contained in a separate sachet and should not be swallowed. 
Sušilno sredstvo iz silikagela je v posebni vrečki in ga ne smete pogoltniti.
Concomitant use of posaconazole and Atripla should be avoided unless the benefit to the patient outweighs the risk. 
Sočasni uporabi pozakonazola in zdravila Atripla se je treba izogibati, razen če so koristi za bolnika večje od tveganja.
Efavirenz may also cause impaired concentration and/or somnolence. 
Efavirenz lahko povzroči tudi motnje koncentracije in/ali somnolenco.
Immune system disorders: Common allergic reaction 
Bolezni imunskega sistema: Pogosti alergijske reakcije
The pharmacokinetics of emtricitabine and tenofovir are similar in male and female patients. 
Farmakokinetične lastnosti emtricitabina in tenofovirja so podobne pri bolnikih moškega in ženskega spola.
• breakdown of muscle, muscle pain or weakness 
• razgradnja mišic, bolečina v mišicah ali šibkost;
The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulphoxide diastereomers (approximately 9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (approximately 4% of dose). 
Biotransformacija emtricitabina vključuje oksidacijo tiolne skupine, pri čemer nastanejo diastereomeri 3'-sulfoksida (približno 9 % odmerka), in konjugacijo z glukuronsko kislino, pri čemer nastane 2'-O-glukuronid (približno 4 % odmerka).
PVR (KM): Pure virologic response assessed using the Kaplan Meier (KM) method M: Missing 
PVR(KM): čisti virološki odziv, ocenjen po metodi Kaplan Meier (KM).
The safety and efficacy of Atripla have not been studied for the treatment of chronic HBV infection. 
Varnosti in učinkovitosti zdravila Atripla pri zdravljenju kronične okužbe s HBV niso raziskovali.
Efavirenz plasma exposure may be increased in patients with homozygous G516T genetic variant of the CYP2B6 isozyme. 
Plazemska izpostavljenost efavirenzu je lahko povečana pri bolnikih s homozigotno genetsko različico G516T izocima CYP2B6.
Because of interpatient variability in these parameters and concerns regarding development of resistance, HIV treatment guidelines should be consulted, also taking into consideration the reason for discontinuation. 
Zaradi razlik pri teh parametrih med posameznimi bolniki in skrbi zaradi razvoja odpornosti je treba upoštevati smernice za zdravljenje okužbe z virusom HIV hkrati z razlogom za prekinitev zdravljenja.
Common cerebellar coordination and balance disturbances3, somnolence (2.0%)3, headache (5.7%)3, disturbance in attention (3.6%)3, dizziness dizziness headache 
Pogosti motnje cerebelarne koordinacije in ravnotežja3, somnolenca (2,0 %)3, glavobol (5,7 %)3, motnje pozornosti (3,6 %)3, omotica omotica glavobol
Cholesterol levels should be periodically monitored. 
Raven holesterola je treba redno spremljati.
The clinical outcome of this observed reduction of boceprevir trough concentrations has not been directly assessed. 
Klinični izid opazovanega zmanjšanja najmanjše koncentracije boceprevira še ni bil neposredno ovrednoten.
In vitro binding of emtricitabine to human plasma proteins is < 4% and independent of concentrations over the range of 0.02 to 200 µg/ml. 
In vitro je bila vezava emtricitabina na človeške plazemske beljakovine < 4 % in neodvisna od koncentracije v razponu med 0,02 in 200 µg/ml.
These immunosuppressants are not anticipated to impact exposure of efavirenz. 
Ni pričakovati vpliva teh imunosupresivov na izpostavljenost efavirenzu.
This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time. 
Zelo je pomembno, da ne prekinete zdravljenja z zdravilom Atripla, saj se količina virusa lahko začne večati, tudi če zdravilo prenehate jemati samo za kratek čas.
Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%). 
Emtricitabin se primarno izloča skozi ledvica - celoten odmerek se izloči z urinom (približno 86 %) in blatom (približno 14 %).
2 Thymidine analogue associated mutations included D67N (n=1) and K70R (n=1). 
2 Mutacije povezane z analogom timidina (TAM = thymidine-analogue associated mutations), vključno z D67N (n=1) in K70R (n=1).
This medicine contains 23.6 mg sodium (main component of cooking/table salt) in each tablet. 
To zdravilo vsebuje 23,6 mg natrija (glavne sestavine kuhinjske soli) na tableto.
Bone toxicity was diagnosed as osteomalacia (monkeys) and reduced bone mineral density (BMD) (rats and dogs). 
Kostna toksičnost je bila diagnosticirana kot osteomalacija (pri opicah) in zmanjšana mineralna gostota kosti (BMD) (pri podganah in psih).
• low white blood cell count (a reduced white blood cell count can make you more prone to infection) 
• majhno število belih krvnih celic (zaradi česar ste lahko bolj dovzetni za okužbo);
Liver enzyme monitoring should be considered for all patients independent of pre-existing hepatic dysfunction or other risk factors. 
Pri vseh bolnikih je treba razmisliti o nadziranju jetrnih encimov, ne glede na predhodni obstoj jetrne disfunkcije ali drugih dejavnikov tveganja.
Osteonecrosis: Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART. 
Osteonekroza: Poročali so o primerih osteonekroze, zlasti pri bolnikih s splošno priznanimi dejavniki tveganja, napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo zdravljenju CART.
While taking Atripla you may still develop infections or other illnesses associated with HIV infection. 
Med jemanjem zdravila Atripla se še vedno lahko pojavijo okužbe ali druge bolezni, povezane z okužbo s HIV.
- Bupropion, a medicine used to treat depression or to help you stop smoking, as your doctor may need to change your dose of bupropion. 
- Bupropion, zdravilo, ki se uporablja za zdravljenje depresije ali za pomoč pri odvajanju od kajenja, ker bo zdravnik morda moral prilagoditi vaš odmerek bupropiona.
Efavirenz exposure may be increased when given with medicinal products (for example ritonavir) or food (for example, grapefruit juice) which inhibit CYP3A4 or CYP2B6 activity. 
Izpostavljenost efavirenzu se lahko poveča, kadar se uporablja z zdravili (npr. z ritonavirjem) ali hrano (npr. s sokom grenivke), ki zavirajo delovanje encimov CYP3A4 ali CYP2B6.
Administration of activated charcoal may be used to aid removal of unabsorbed efavirenz. 
Za odstranitev neabsorbiranega efavirenza se lahko uporabi aktivno oglje.
- anorexia 
- anoreksija.
It is recommended that Atripla be taken on an empty stomach, preferably at bedtime. 
Priporočamo, da se zdravilo Atripla jemlje na prazen želodec, po možnosti pred spanjem.
Monitoring of renal function may be indicated, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents. 
Morda bo potrebno spremljati ledvično funkcijo, še posebej pri bolnikih s spremljajočo sistemsko ali ledvično boleznijo ali pa pri bolnikih, ki jemljejo nefrotoksična zdravila.
Stevens-Johnson syndrome, erythema multiforme3, severe rash angioedema4 
Stevens-Johnsonov sindrom, multiformni eritem3, hud izpuščaj angioedem4
Efavirenz: no clinically significant interaction. 
efavirenz: ni klinično pomembnih interakcij.
Patients should be advised that if they experience symptoms such as severe depression, psychosis or suicidal ideation, they should contact their doctor immediately to assess the possibility that the symptoms may be related to the use of efavirenz, and if so, to determine whether the risk of continued therapy outweighs the benefits (see section 4.8). 
Bolnikom je treba svetovati, naj se v primeru pojava simptomov, kot so huda oblika depresije, psihoza ali misel na samomor, nemudoma posvetujejo s svojim zdravnikom, ki bo ocenil, ali so simptomi povezani z jemanjem efavirenza, in odločil, ali je tveganje nadaljevanja zdravljenja z efavirenzom večje od koristi (glejte poglavje 4.8).
If you are taking any of these medicines, your doctor may need to check the level of anticonvulsant medicine in your blood to ensure that it is not affected while taking Atripla. 
Če jemljete katerokoli od teh zdravil, bo zdravnik morda moral preveriti raven zdravila proti epilepsiji v krvi, da se prepriča, da se med jemanjem zdravila Atripla ni spremenila.
The oral bioavailability of tenofovir from tenofovir disoproxil in fasted patients was approximately 25%. 
Peroralna biološka uporabnost tenofovirja iz dizoproksiltenofoviratapri teščih bolnikih je bila približno 25 %.
- You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. 
- Med jemanjem tega zdravila lahko še vedno prenesete okužbo s HIV na druge, čeprav učinkovito protiretrovirusno zdravljenje to tveganje zmanjša.
Pharmacokinetic studies have not been performed with Atripla in infants and children under 18 years of age (see section 4.2). 
Farmakokinetičnih študij z zdravilom Atripla pri dojenčkih in otrocih, starih manj kot 18 let, niso opravili (glejte poglavje 4.2).
In uninfected volunteers, multiple doses of 200 to 400 mg per day for 10 days resulted in a lower than predicted extent of accumulation (22 to 42% lower) and a shorter terminal half-life of 40 to 55 hours (single dose half-life 52 to 76 hours). 
Pri neokuženih prostovoljcih so 10-dnevni večkratni odmerki 200-400 mg dnevno povzročili manjšo akumulacijo zdravila od pričakovane (22-42 % manjšo) in krajši končni razpolovni čas 40-55 ur (razpolovni čas enkratnega odmerka je 52-76 ur).
Laboratory tests should be performed to evaluate their liver disease at periodic intervals (see section 4.2). 
Za ocenjevanje njihove jetrne bolezni je treba v rednih presledkih opravljati laboratorijske preiskave (glejte poglavje 4.2).
Interaction only studied with sofosbuvir/velpatasvir. 
Interakcije so preučili samo s sofosbuvirjem/velpatasvirjem.
These are listed under Do not take Atripla, at the start of section 2. 
Ta zdravila so navedena v razdelku Ne jemljite zdravila Atripla, na začetku drugega poglavja.
Do not take a double dose to make up for a forgotten tablet. 
Ne vzemite dvojnega odmerka, da bi nadomestili izpuščenega.
- Independent of a history of liver disease, your doctor will consider regular blood tests to check how your liver is working. 
Neodvisno od tega, ali imate jetrno bolezen v anamnezi, bo vaš zdravnik razmislil o rednih krvnih preiskavah, da preveri, kako delujejo vaša jetra.
- if you have a heart disorder, such as abnormal electrical signal called prolongation of the QT interval. 
- če imate bolezen srca, kot je nenormalen električni signal, kar se imenuje podaljšanje intervala QT.
Following oral administration, the elimination half-life of emtricitabine is approximately 10 hours. 
Po peroralni uporabi je razpolovni čas izločanja emtricitabina približno 10 ur.
It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy with Atripla and renal function (creatinine clearance and serum phosphate) is also monitored after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors. 
Pred začetkom zdravljenja z zdravilom Atripla je priporočljivo določiti kreatininski očistek pri vseh bolnikih in spremljati delovanje ledvic (očistek kreatinina in koncentracija fosfatov v serumu) po dveh do štirih tednih zdravljenja, po treh mesecih zdravljenja in zatem vsake tri do šest mesecev pri bolnikih brez dejavnikov tveganja za ledvice.
abnormal dreams, insomnia 
nenavadne sanje, nespečnost
These problems tend to occur more often in those who have a history of mental illness. 
Te težave se pogosteje pojavijo pri bolnikih z duševno boleznijo v anamnezi.
The breakdown of muscle, softening of the bones (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness and decreases in potassium or phosphate in the blood may occur due to damage to kidney tubule cells. 
Razgradnja mišic, mehčanje kosti (z bolečino v kosteh in včasih zlomi), bolečina v mišicah, mišična šibkost in znižanje ravni kalija ali fosfatov v krvi so lahko posledica poškodbe celic ledvičnih tubulov.
If there is evidence of worsening liver disease or persistent elevations of serum transaminases to greater than 5 times the upper limit of the normal range, the benefit of continued therapy with Atripla needs to be weighed against the potential risks of significant liver toxicity. 
Če obstaja dokaz za poslabšanje jetrne bolezni ali če se pojavijo trdovratna zvišanja serumskih transaminaz na več kot 5-kratno zgornjo mejo normalne vrednosti, je treba pretehtati korist nadaljevanja zdravljenja z zdravilom Atripla in možna tveganja pomembne toksičnosti za jetra.
Efavirenz has also been shown to induce UGT1A1. 
Izkazalo se je, da efavirenz spodbuja tudi UGT1A1.
• decreased sexual drive 
• zmanjšana želja po spolnosti;
• difficulty sleeping, abnormal dreams, difficulty concentrating, drowsiness 
• težave s spanjem, nenormalne sanje, težave s koncentracijo, dremavost;
• damage to kidney tubules 
• poškodbe ledvičnih tubulov.
If you think you may have lactic acidosis, contact your doctor immediately. 
Če menite, da imate laktacidozo, se takoj posvetujte s svojim zdravnikom.
Patients receiving Atripla or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases. 
Pri bolnikih, ki prejemajo zdravilo Atripla ali katerokoli drugo protiretrovirusno zdravljenje, se lahko še naprej pojavljajo oportunistične okužbe in drugi zapleti okužbe z virusom HIV, zato morajo ostati pod skrbnim nadzorom zdravnikov z izkušnjami pri zdravljenju bolnikov z boleznimi, povezanimi s HIV.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects. 
Pri otrocih, katerih matere so med nosečnostjo jemale nukleozidne zaviralce reverzne transkriptaze (NRTI, nucleoside reverse transcriptase inhibitors), je korist zaščite pred virusom HIV odtehtala tveganje za neželene učinke.
Combination of emtricitabine and tenofovir disoproxil: Genotoxicity and repeated-dose toxicity studies of one month or less with the combination of these two components found no exacerbation of toxicological effects compared to studies with the separate components. 
Kombinacija emtricitabina in dizoproksiltenofovirata: Študije genotoksičnosti in toksičnosti pri ponavljajočih se odmerkih, ki so trajale en mesec ali manj pri kombinaciji teh dveh učinkovin, niso pokazale poslabšanja toksikoloških učinkov v primerjavi s študijami posameznih učinkovin.
The net effect of co-administration is not clear. 
Neto učinek sočasne uporabe ni razjasnjen.
Atripla should be taken on an empty stomach (commonly defined as 1 hour before or 2 hours after a meal) preferably at bedtime. 
Zdravilo Atripla morate jemati na prazen želodec (kar pomeni 1 uro pred ali 2 uri po obroku), najbolje zvečer pred spanjem.
Please refer to the Summary of Product Characteristics for these medicinal products. 
Prosimo, glejte Povzetke glavnih značilnosti teh posameznih zdravil.
Total active HMG Co-A reductase inhibitors: 
Skupni aktivni zaviralci HMG Co-A reduktaze:
If this is unavoidable, your doctor will monitor your kidney function once a week. 
Če se sočasnemu jemanju ni mogoče izogniti, bo vaš zdravnik enkrat tedensko preverjal delovanje ledvic.
Patients either changed to Atripla (N=203) or continued on their original antiretroviral treatment regimen (N=97). 
Bolniki so zamenjali zdravljenje in začeli prejemati zdravilo Atripla (N=203) ali pa so nadaljevali prvotno protiretrovirusno zdravljenje (N = 97).
These side effects may start in the first 1 or 2 days of treatment and usually go away after the first 2 to 4 weeks. 
Ti neželeni učinki se lahko pojavijo v prvem dnevu ali prvih dveh dneh zdravljenja in navadno izginejo po prvih dveh do štirih tednih.
The potential for interactions with efavirenz and other azole antifungals, such as ketoconazole, has not been studied. 
Možnosti interakcij efavirenza in drugih azolskih antimikotikov, kot je ketokonazol, niso raziskovali.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products. 
Pri sočasnem protivirusnem zdravljenju hepatitisa B ali C glejte ustrezne Povzetke glavnih značilnosti teh zdravil.
Findings in the rat and monkey studies indicated that there was a substance-related decrease in intestinal absorption of phosphate with potential secondary reduction in BMD. 
Ugotovitve pri študijah na podganah in opicah kažejo, da je prišlo do z učinkovino povezanega zmanjšanja črevesne absorpcije fosfata s potencialnim sekundarnim zmanjšanjem BMD.
Because of the long half-life of efavirenz, use of adequate contraceptive measures for 12 weeks after discontinuation of Atripla is recommended. 
Zaradi dolgega razpolovnega časa efavirenza priporočamo uporabo ustrezne kontracepcije še 12 tednov po prekinitvi zdravljenja z zdravilom Atripla.
The mean plasma to blood concentration ratio was approximately 1.0 and the mean semen to plasma concentration ratio was approximately 4.0. 
Povprečje razmerja koncentracije v plazmi in krvi je bilo približno 1,0, razmerje koncentracije v spermi in plazmi pa približno 4,0.
Use of Atripla in combination with saquinavir as the sole protease inhibitor is not recommended. 
Uporaba zdravila Atripla v kombinaciji s sakvinavirjem kot edinim zaviralcem proteaze ni priporočljiva.
Approximately 14 to 34% of a radiolabelled dose of efavirenz was recovered in the urine and less than 1% of the dose was excreted in urine as unchanged efavirenz. 
Približno 14-34 % radioaktivno označenega odmerka efavirenza se je izločilo z urinom, manj kot 1 % odmerka pa se je z urinom izločilo v obliki nespremenjenega efavirenza.
However, in some patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil discontinuation. 
Vendar pa pri nekaterih bolnikih upad očistka kreatinina ni povsem izzvenel, kljub prekinitvi dizoproksiltenofovirata.
Atripla is not usually taken with other medicines that can damage your kidneys (see Other medicines and Atripla). 
Zdravilo Atripla se po navadi ne jemlje skupaj z drugimi zdravili, ki lahko škodijo ledvicam (glejte Druga zdravila in zdravilo Atripla).
Use of Atripla should be avoided with concurrent or recent use of a nephrotoxic medicinal product. 
Uporabi zdravila Atripla se je treba izogibati pri sočasni ali nedavni uporabi nefrotoksičnih zdravil.
Norelgestromin (active metabolite): 
norelgestromin (aktivni presnovek):
Efavirenz may be an inducer of CYP2C19 and CYP2C9; however, inhibition has also been observed in vitro and the net effect of co-administration with substrates of these enzymes is not clear (see section 5.2). 
Efavirenz je morda induktor encimov CYP2C19 in CYP2C9; vendar so in vitro opazili tudi zaviranje in neto učinek sočasne uporabe s substrati teh encimov ni razjasnjen (glejte poglavje 5.2).
Data are available from 286 patients who switched to Atripla: 160 had previously received efavirenz, emtricitabine and tenofovir disoproxil, and 126 had previously received Combivir and efavirenz. 
Na voljo so podatki o 286 bolnikih, ki so prešli na zdravilo Atripla: 160 jih je predhodno prejemalo efavirenz, emtricitabin in dizoproksiltenofovirat, 126 pa zdravilo Combivir ter efavirenz.
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). 
Pri nekaterih bolnikih, ki jemljejo kombinirano protiretrovirusno zdravljenje, se lahko pojavi bolezen kosti, imenovana osteonekroza (smrt kostnega tkiva zaradi slabše prekrvavitve v kosteh).
Modified LOCF: Post-hoc analysis where patients who failed virologically or discontinued for adverse events were treated as failures; for other drop-outs, the LOCF (last observation carried forward) method was applied 
Prilagojeni LOCF: Post-hoc analiza pri kateri so bili bolniki z virusnim neodzivom in bolniki pri katerih je bilo zdravljenje prekinjeno zaradi pojava neželenih učinkov obravnavani kot neuspeh; pri ostalih izključenih bolnikih pa je bila uporabljena metoda LOCF (last observation carried forward).
This loss is due to significant decreases in elbasvir/grazoprevir plasma concentrations caused by CYP3A4 or P-gp induction. 
Ta izguba je posledica pomembnega zmanjšanja koncentracij elbasvirja/grazoprevirja v plazmi, ki jih povzroči indukcija CYP3A4 ali P-gp.
Exposures of raltegravir (a UGT1A1 substrate) are reduced in the presence of efavirenz (see section 4.5, Table 1). 
Izpostavljenost raltegravirju (substratu UGT1A1) se v prisotnosti efavirenza zmanjša (glejte poglavje 4.5, Tabela 1).
The bone toxicity in young adult rats and dogs occurred at exposures ≥ 5-fold the exposure in paediatric or adult patients; bone toxicity occurred in juvenile infected monkeys at very high exposures following subcutaneous dosing (≥ 40-fold the exposure in patients). 
Kostna toksičnost pri mladih odraslih podganah in psih se je pojavila pri izpostavljenostih, ki so bile ≥ 5-krat večje od izpostavljenosti pri pediatričnih ali odraslih bolnikih, kostna toksičnost pa se je pojavila pri mladih okuženih opicah pri zelo visokih izpostavljenostih po subkutanem odmerjanju (≥ 40-kratna izpostavitev pri bolnikih).
Most cases occurred in patients who already had liver disease, but there have been a few reports in patients without any existing liver disease 
Ta učinek se je pojavil večinoma pri bolnikih z obstoječo jetrno boleznijo, vendar pa obstaja nekaj poročil o pojavu pri bolnikih, ki prej niso imeli jetrne bolezni;